Femasys (FEMY) Cash from Investing Activities (2020 - 2026)
Femasys (FEMY) posted Cash from Investing Activities of -$79138.0 for Q1 2026, up 59.77% on a QoQ basis from -$196715.0 in Q4 2025, and up 18.08% year-over-year from -$67020.2 in Q1 2025.
Femasys (FEMY) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Femasys' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$79138.0 for Q1 2026.
- Quarterly Cash from Investing Activities rose 18.08% year-over-year to -$79138.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$612631.0 (up 28.28% YoY) and the FY2025 annual result came in at -$630098.0, up 25.68% from the prior year.
- Cash from Investing Activities was -$79138.0 for Q1 2026 at Femasys, up from -$196715.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$8901.0 in Q1 2023 and bottomed at -$440028.0 in Q3 2024.
- A 5-year average of -$124023.1 and a median of -$96605.0 in 2025 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 92.61% — and 2024, when it tumbled 1519.6%.
- Femasys' Cash from Investing Activities stood at -$93877.0 in 2022, then surged by 52.17% to -$44899.0 in 2023, then plunged by 146.36% to -$110613.0 in 2024, then plunged by 77.84% to -$196715.0 in 2025, then soared by 59.77% to -$79138.0 in 2026.
- Business Quant data shows FEMY's Cash from Investing Activities at -$79138.0 in Q1 2026, -$196715.0 in Q4 2025, and -$239816.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | -218.00 Mn |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | -26.60 Mn |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | -139.00 Mn |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | -96.00 Mn |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | -58.03 Mn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | -43.20 Mn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | -90.00 Mn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | -77.00 Mn |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | -131.58 Mn |
| 10 | Femasys | 17.46 Mn | 12.07 Mn | - | -79,138.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79,138.00 |
| Mar 31, 2026 | -79,138.00 |
| Dec 31, 2025 | -196,715.00 |
| Dec 31, 2025 | -196,715.00 |
| Sep 30, 2025 | -239,816.00 |
| Sep 30, 2025 | -239,816.00 |
| Jun 30, 2025 | -96,962.00 |
| Jun 30, 2025 | -96,962.00 |
| Mar 31, 2025 | -96,605.00 |
| Mar 31, 2025 | -96,605.00 |
| Dec 31, 2024 | -110,613.00 |
| Dec 31, 2024 | -110,613.00 |
| Sep 30, 2024 | -440,028.00 |
| Sep 30, 2024 | -440,028.00 |
| Jun 30, 2024 | -206,963.00 |
| Jun 30, 2024 | -206,963.00 |
| Mar 31, 2024 | -90,160.00 |
| Mar 31, 2024 | -90,160.00 |
| Dec 31, 2023 | -44,899.00 |
| Dec 31, 2023 | -44,899.00 |